Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Ltd has announced a Board of Directors meeting scheduled for July 17, 2026. The primary agenda is to consider, approve, and take on record the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. In line with the company's insider trading code, the trading window for designated persons will be closed from July 1, 2026, until 48 hours after the financial results are publicly disclosed. The information is also available on the company's website.

Tatva Chintan Pharma Chem Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code. The trading window will be shut from Wednesday, July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. During this period, no trading in the company's securities is permitted for these individuals.

Tatva Chintan Pharma Chem Ltd's board re-appointed M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for the financial year 2026-27. These appointments, based on the Audit Committee's recommendation, were approved during the board meeting held on May 16, 2026. The board also approved the audited financial results for the quarter and year ended March 31, 2026, and recommended a final dividend of ₹2 per equity share, subject to shareholder approval.

The Board of Directors of Tatva Chintan Pharma Chem Ltd approved the audited financial results for the quarter and financial year ended March 31, 2026. They recommended a final dividend of ₹2 (20%) per equity share for FY26, subject to shareholder approval. Additionally, the board approved the appointment of M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for FY27.

The Board of Directors of Tatva Chintan Pharma Chem Ltd approved the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026. They recommended a final dividend of ₹2 (20%) per equity share of ₹10 each for FY26, subject to shareholder approval. The board also approved the appointment of M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for FY27.

The Board of Directors of Tatva Chintan Pharma Chem Limited approved a final dividend of ₹2 (20%) per equity share of ₹10 each for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting. The board also approved the appointment of M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech Private Limited as Internal Auditor for FY 2026-27.

Tatva Chintan Pharma Chem Ltd has scheduled a Board of Directors meeting on May 16, 2026, to consider and approve the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider recommending a final dividend for FY26, subject to shareholder approval. The trading window for designated persons has been closed from April 1, 2026, until 48 hours after the financial results are made public.

Tatva Chintan Pharma Chem Ltd has announced the closure of the trading window for all designated persons and their immediate relatives, in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code on prohibition of insider trading. The closure will be effective from Wednesday, 01 April 2026, until 48 hours after the declaration of the audited financial results for the quarter and financial year ending 31 March 2026. Designated persons and their immediate relatives are advised not to trade in the securities of the company during this period.

Tatva Chintan Pharma Chem Ltd. has received a communication from Gujarat Gas Limited regarding the Natural Gas (Supply Regulation) Order, 2026, issued by the Ministry of Petroleum and Natural Gas, Government of India. This order, issued under the Essential Commodities Act, 1955, regulates the allocation and pricing of natural gas due to geopolitical conflicts in the Middle East. The new regulatory framework mandates a 20% reduction in gas supply to industrial consumers, including Tatva Chintan's manufacturing facilities, and implements a Pooled Price mechanism for gas allocation. This government mandate is classified as a Force Majeure mitigation measure and supersedes existing provisions of the Gas Sales Agreement. The company has made arrangements for alternative fuel sources and process optimization to minimize the impact on output. The potential financial impact of this shortage and the revised pricing mechanism cannot be fully quantified at this stage.

Tatva Chintan Pharma Chem Ltd has entered into a Power Purchase Agreement (PPA) with AMPIN C&I Power Twenty Six Private Limited. The Company will also be acquiring equity shares of AMPIN C&I Power Twenty Six Private Limited, which is a Special Purpose Vehicle (SPV) set up for the purpose of setting up Renewable Power Plants in Gujarat with a Solar Capacity of 9.9 MW AC and Wind Capacity of 9.9 MW. The SPV will supply 3.2 MW of solar and 3.2 MW of wind power to the Company under the Group Captive Power Scheme. This will enable Tatva Chintan Pharma Chem Ltd to source environment friendly Green Energy (Wind and Solar) for long-term captive consumption upon implementation of the subject project by the SPV and would help in reducing the energy costs of the Company significantly. This aligns with the Company's commitment to increasing the share of renewable power in operations while ensuring compliance as a 'captive user' under Indian electricity laws.